Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same.

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Startup SpringWorks Therapeutics and BeiGene Ltd. are teaming up to find out if a combination of two cancer treatments can help patients. SpringWorks launched last year with $103 million in ...

SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company ...

SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while ...

SpringWorks Therapeutics received FDA approval for Ogsiveo, its treatment for adult patients with desmoid tumors. Click here to read an analysis of SWTX stock.

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.